Bentley announced at this year’s Leipzig Interventional Course (LINC 2023; 6–9 June, Leipzig, Germany) that it has reached an important milestone: having sold the 300,000th BeGraft. This milestone was celebrated at the Bentley booth at LINC.
After launching the first BeGraft in 2012, the product found its way quickly to the clinics carrying out the most advanced and challenging endovascular procedures. The BeGraft is available in over 80 countries and has become the market leader in most of them.
Martijn Nugteren, director sales and marketing at Bentley, is delighted with this six-figure number and mentioned in a statement: “It is amazing what we have achieved with the BeGraft in such a short time. We have been able to treat so many patients globally, giving them the best stent for the treatment of their vascular disease.” He also highlighted that “thanks to the acquisition of Qmedics in mid-April, Bentley is ready for the future growth of the BeGraft covered stent portfolio, which is much needed with the expected new indication and state-of-the art pipeline that we have.”
The 300,000th BeGraft was sold to the company NovaHealth in Thailand, which has been a partner of Bentley since 2015.
